Interest Income Expense - Maat Pharma SA (PAR:MAAT) - Alpha Spread
M

Maat Pharma SA
PAR:MAAT

Watchlist Manager
Maat Pharma SA
PAR:MAAT
Watchlist
Price: 7.3 EUR 2.24% Market Closed
Market Cap: 101.4m EUR
Have any thoughts about
Maat Pharma SA?
Write Note

Maat Pharma SA
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Maat Pharma SA
Interest Income Expense Peer Comparison

Comparables:
VLA
NANO
IPH
GNFT
ALERS

Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
M
Maat Pharma SA
PAR:MAAT
Interest Income Expense
-€402k
CAGR 3-Years
-107%
CAGR 5-Years
-41%
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Interest Income Expense
-€44.1m
CAGR 3-Years
-90%
CAGR 5-Years
-129%
CAGR 10-Years
-46%
Nanobiotix SA
PAR:NANO
Interest Income Expense
-€13.1m
CAGR 3-Years
N/A
CAGR 5-Years
-105%
CAGR 10-Years
N/A
Innate Pharma SA
PAR:IPH
Interest Income Expense
€2.5m
CAGR 3-Years
N/A
CAGR 5-Years
89%
CAGR 10-Years
31%
Genfit SA
NASDAQ:GNFT
Interest Income Expense
-€3.4m
CAGR 3-Years
43%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Interest Income Expense
-€3.6m
CAGR 3-Years
-66%
CAGR 5-Years
-25%
CAGR 10-Years
-43%

See Also

What is Maat Pharma SA's Interest Income Expense?
Interest Income Expense
-402k EUR

Based on the financial report for Dec 31, 2023, Maat Pharma SA's Interest Income Expense amounts to -402k EUR.

What is Maat Pharma SA's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
-41%

Over the last year, the Interest Income Expense growth was -187%. The average annual Interest Income Expense growth rates for Maat Pharma SA have been -107% over the past three years , -41% over the past five years .

Back to Top